Zyprexa

Simply click the links below.

NEWS Dicta Features Federal Court Madison County New Lawsuits St.

Clair County Ill.

Appellate Court Ill.

Supreme Court Q & A NEWS ARCHIVE THE DOCKET Tuesday, Jan.

17 Friday, Jan.

13 Thursday, Jan.

12 Wednesday, Jan.

11 Monday, Jan.

9 THE DOCKET ARCHIVE ARGUMENTS Cartoons Letters to the Editor Our View Their View ARGUMENTS ARCHIVE PHOTOS All that glitters - 12/19/2005Good cheer!

- 12/14/2005Wheels for Christmas - 12/14/2005PHOTOS ARCHIVES ASBESTOS DOCKET Asbestos Motion Docket: Tuesday, Jan.

17 Asbestos Jury Docket: Tuesday, Jan.

17 ASBESTOS DOCKET ARCHIVE ABOUT US Legal Notices for Publication Place a Classified ad Where can you find the print edition of The Record ?

Contact The Record By way of introduction ADVERTISING You can advertise in The Record!

UPCOMING EVENTS Eagle Meet and Greet (Community) - 1/14Eagle Meet and Greet (Community) - 1/21Eagle Meet and Greet (Com...

"It's a positive for the group," said Shibutani, of the "Investors now see that intellectual property is not being chopped off at its knees."Shibutani added that after three Vioxx verdicts, investors appear a little more at ease, now that they have more visibility into the litigation."People are now having more reasons to be positive about the products," said Shibutani.The lure of niche markets Another trend that will be discussed this year is the subtle move by some of Big Pharma away from blockbuster drugs for huge patient populations and towards specialty drugs, such as those developed by biotech companies, which are easier to market."We're starting to see a changing of the pharmaceutical model from primary products to specialty products," said Shibutani, adding that Wyeth, Bristol-Myers and Merck, in particular, are repositioning themselves in this manner.

Wyeth and Merck will both be presenting at the conference.As the trend continues, Shibutani says investors will see the already fuzzy line between biotechnology and pharmaceuticals blurred ...